通过工程化贪来实现表达依赖性瘤预定目标
Abbigael Harthorn1, Tse-Han Kuo2, Sarah W Torres1
1Department of Biomedical Engineering, University of Minnesota-Twin Cities, Minneapolis, Minnesota 55455, United States.
Molecular pharmaceutics
|December 20, 2024
概括
设计了一种用于癌症治疗的新型结合平台,该平台使用激情驱动的特异性来精确瘤向,提高选择性并减少预定向放射性子治疗中的副作用.
科学领域:
- 生物技术是生物技术.
- 在瘤学瘤学.
- 分子工程分子工程分子工程
背景情况:
- 选择性向瘤细胞输送癌症治疗药物至关重要,但由于缺乏真正特定的生物标志物而受到限制.
- 对健康组织的非特异性结合会导致瘤外的瘤毒性,限制治疗窗口.
研究的目的:
- 为表达依赖性瘤向设计一个先进的结合平台,提高癌症治疗的选择性.
- 开发一个依赖于热情而不是二元生物标志物存在的系统,以改善准.
主要方法:
- 针对与癌胚抗原相关的细胞粘附分子5 (CEACAM5) 和叶酸受体1 (FolR1) 具有多种单体亲属性的工程亲属体.
- 通过将附属体连接到纳米体来构建双特异性,三价值蛋白质,用于预定向的放射性联体疗法.
- 在混合细胞培养中评估表达依赖的向和选择性.
主要成果:
- 实现了对CEACAM5 (110nM亲和力) 和FolR1 (250nM亲和力) 的附属体的表达依赖向.
- 使用双特异的三价构造,在高和低FolR1表达细胞之间展示了超过25倍的差异化.
- 开发了一种尺寸高效的双价分子,具有类似的选择性和可溶性抗原的最小抑制.
结论:
- 激情驱动的特异性使得精确的,表达依赖的瘤向,克服了传统基于生物标志物的方法的局限性.
- 该工程平台提供了增强的选择性和减少对可溶性抗原干扰的敏感性,以改善癌症治疗方法.
- 这项工作为预定向放射性干治疗中先进的瘤向策略提供了新的设计原则.
相关概念视频
01:27Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K